Fate therapeutics announces treatment of first patient in landmark phase 1 clinical trial of ft819, the first-ever ipsc-derived car t-cell therapy

Off-the-shelf car t-cell product candidate derived from clonal master ipsc line with novel cd19-specific 1xx car integrated into trac locus

FATE Ratings Summary

FATE Quant Ranking